Litigation Watch: Top focus names for Q3
MDC follows significant legal disputes to provide clients with actionable investment ideas. Focus List situations that they believe may be among the most actionable during Q3 include Burford Capital, Reckitt Benckiser and Bayer. Burford is a UK based litigation funder that has already been awarded a Judgment totalling $16,099,788,293. Now, the challenge is to collect from the Republic of Argentina! Reckitt along with Abbott Laboratories are facing product liability lawsuits in the US regarding baby formula products causing NEC. The next bellwether trial will be in the Diggs Case scheduled to start on Aug 8th. As if Bayer hasn't faced enough toxic tort litigation regarding its Roundup weed killer product, it now faces potential liability for Polychlorinated Biphenyls. The next PCB Trial is scheduled to commence on Sep 8th.
Edition: 215
- 11 July, 2025
Special Sits Idea Forum
MYST’s latest buyside event saw a large group of investors offer a diverse set of ideas spanning various sectors / themes. Stocks highlighted include:
Bayer (BAYN GR) - New management advancing turnaround as litigation resolution approaches. TP €40 (65% upside).
CRH (CRH) - Increased pricing power + Ukraine rebuild opportunity to narrow valuation gap vs. peers. TP $135 (35% upside).
NFI (NFI CN) - Earnings / margins to rebound sharply as production issues ease. TP C$40 (200% upside).
Paramount Global (PARA) - Pending deal approval to trigger “structural bid” from Arbs while streaming business inflects. TP $15 (30% upside).
Parkland (PKI CN) - Substantial SOTP upside amid ongoing strategic alternatives process. TP C$54 (45% upside).
Edition: 207
- 21 March, 2025
Event-Driven Legal℠ investment-research opportunities
MDC follows significant legal disputes to provide clients with actionable investment ideas that tend to be non-correlated with the market. They currently believe that the following companies will likely be involved in significant litigation in 2025 and 2026: Abbott Laboratories, Avadel Pharmaceuticals, Axsome Therapeutics, Bausch Health, Bayer, Burford Capital, Corcept Therapeutics, Exelixis, GSK, Harmony Biosciences, Johnson & Johnson, Liquidia, Live Nation, Reckitt and Sotera Health.
Edition: 205
- 21 February, 2025
Bayer (BAYN GR) Germany
Healthcare
ROCGA’s Cash Flow Returns On Investments based DCF valuation platform shows BAYN to be undervalued for the first time in 10 years. BAYN is not a quality company and would not warrant attention, but the valuation gap is compelling with potentially 50% upside. With a few clicks, you can model and value one of 2000 companies across Europe and the US. Other companies that appear on their list of undervalued companies are Ahold, Associated British Foods and Saint-Gobain. A free consultation and trial can be arranged on request.
Edition: 176
- 22 December, 2023
Special Situations Idea Forum
Presenters at MYST’s latest buy-side event offered a diverse set of ideas with significant (50%+) upside spanning almost every major sector. Highlights include:
Alight (ALIT) - Imminent removal of Blackstone supply overhang to cause shares to re-rate towards peers. TP $20 (100% upside).
Bayer (BAYN GR) - Forgotten stock with activist involvement to push for potential Monsanto spin. TP €82 (60% upside).
Equitrans Midstream (ETRN) - Completion of long-delayed pipeline to drive EBITDA inflection + takeover target. TP $16.50 (80% upside).
Golar LNG (GLNG) - Simplified LNG play with several enormous contracts finally nearing fruition. TP $40 (65% upside).
Secure Energy Services (SES CN) - Waste co. disguised as an oil services co. poised for material re-rating. TP C$13 (100% upside).
Edition: 165
- 21 July, 2023
Bayer (BAYN GR) Germany
Healthcare
Evidence suggests new CEO Bill Anderson will use R&D, M&A and transformation to grow earnings - Paragon interviewed former colleagues who worked with Anderson at Genentech and Roche for over 75 years combined. Sources were unanimously positive, citing his knowledge, leadership abilities, management style and ability to drive results at both companies. Following his appointment, all but one source would consider investing in BAYN with the one hold out citing concerns about the cultural differences between a traditional German company and a new CEO with an informal, “Californian” management style.
Edition: 164
- 07 July, 2023
The future is on our plate
Against the background of a growing world population, our food system is considered unfit for purpose as it entails unsustainable or socially unacceptable environmental, animal and health costs. Agriculture and the food industry are responsible for about a quarter of global greenhouse gas emissions, largely because of animal farming. What is more, diets are biased towards animal fats, which have potentially detrimental health effects. Piers Nestler looks at the possible implications for the industry as he tries to identify beneficiaries from a transition to alternative proteins. Companies discussed BASF, Bayer, Biotalys, Danone, GEA, Kerry Group, KWS Saat and Vilmorin.
Edition: 141
- 05 August, 2022
The inevitable rise of agtech and how to play it
The inevitable growth of agtech, with its $300bn market growing at 7% CAGR, should not be overlooked. Companies in the industry offer attractive returns in excess of the cost of capital, consistently outperforming across the cycle. Dan Waterman delves deep into the market and identifies companies positively exposed to agtech themes, including ACGO, Deere, Genus, Zoetis, Darling Ingredients and Novozymes. Expect agchem manufacturers to feel the pressure in the face of increasing regulation, including BASF, Bayer and Nufarm.
Edition: 127
- 21 January, 2022